Evidence map›Paper›PMID 41280002›Full record

ArticlebioRxiv : the preprint server for biology2025

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate.

Roberta Buono, Dennis Juarez, Madhuri Paul, Sarah J Skuli, Ian B Wong, Ishita Tarnekar, Zhili Ying, Izabelle Le, Gerald Wertheim, A'ishah Bakayoko and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Roberta BuonoDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Dennis JuarezDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Madhuri PaulDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Sarah J SkuliDepartment of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ian B WongDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Ishita TarnekarDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Zhili YingDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.
Izabelle LeDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, Department of Chemistry, University of California Irvine, Irvine, CA, 92697, USA.
Gerald WertheimDepartment of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
A'ishah BakayokoDepartment of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marisa KruidenierDepartment of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Said M SebtiDepartment of Pharmacology and Toxicology and Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Marina KonoplevaAlbert Einstein Colege of Medicine, Montefiore Einstein Comprehensive Cancer Center, 1300 Morris Park Ave, Bronx, NY, 10461, USA.
Angela G FleischmanDivision of Hematology-Oncology, Department of Medicine, University of California Irvine, Irvine, CA, 92697, USA.
Cholsoon JangDepartment of Biological Chemistry, Center for Epigenetics and Metabolism, Department of Chemistry, University of California Irvine, Irvine, CA, 92697, USA.
Martin CarrollDepartment of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-5622-3735
David A FrumanDepartment of Molecular Biology & Biochemistry, University of California Irvine, Irvine, CA, 92697, USA.ORCID 0000-0002-1796-5162

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
University of Pennsylvania Patient-derived Xenograft Development and Trials CenterU54CA283759 · NCI · UNIVERSITY OF PENNSYLVANIA · PI MARTIN CARROLL · 2023 to 2026
$5.1M
Elucidating dietary fructose and alcohol interactions during liver cancer developmentR01AA029124 · NIAAA · UNIVERSITY OF CALIFORNIA-IRVINE · PI JANG, CHOLSOON · 2021 to 2025
$2.0M
BLRD VA I01 BX000918NCI NIH HHS P30 CA062203NCI NIH HHS T32 CA009054NCI NIH HHS U54 CA283759NIAAA NIH HHS R01 AA029124
6 · The paper itself

Abstract

The BCL2 inhibitor venetoclax has therapeutic activity in several hematological malignancies. In acute myeloid leukemia (AML), venetoclax combined with hypomethylating agents is the standard of care for patients unfit for intensive chemotherapy, but intrinsic and acquired resistance are common. Loss of p53 function is strongly associated with venetoclax resistance, and adding venetoclax to 5-azacitidine provides no overall survival benefit in

Identifiers

PMID41280002
PMCPMC12636571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.